Literature DB >> 180244

Human fibroblast and leukocyte interferons show different dose-response curves in assay of cell protection.

V G Edy, A Billiau, P De Somer.   

Abstract

Preparations of human fibroblast and leukocyte interferons of similar potency show markedly different dose-response curves in an assay which measures the degree of protection of tissue cultures against virus c.p.e. The effect is observed with both vesicular stomatitis virus (VSV) and Mengovirus, and is not altered by purification of the interferons.

Entities:  

Mesh：

Substances：

Year:  1976        PMID： 180244     DOI： 10.1099/0022-1317-31-2-251

Source DB:  PubMed          Journal:  J Gen Virol        ISSN： 0022-1317            Impact factor:   3.891


  7 in total

1.  Presence of human chromosome 21 alone is sufficient for hybrid cell sensitivity to human interferon.

Authors:  D L Slate; L Shulman; J B Lawrence; M Revel; F H Ruddle
Journal:  J Virol       Date:  1978-01       Impact factor: 5.103

2.  Requirement for macrophages for interferon to be effective against encephalomyocarditis virus infection of mice.

Authors:  N Stebbing; K M Dawson; I J Lindley
Journal:  Infect Immun       Date:  1978-01       Impact factor: 3.441

3.  Stable and unstable forms of human fibroblast interferon.

Authors:  V G Edy; J Desmyter; A Billiau; P De Somer
Journal:  Infect Immun       Date:  1977-05       Impact factor: 3.441

Review 4.  Differences between human alpha (leukocyte) and beta (fibroblast) interferons.

Authors:  T G Hayes
Journal:  Arch Virol       Date:  1981       Impact factor: 2.574

5.  Production of interferon by human tumor cell lines.

Authors:  P Jameson; S E Grossberg
Journal:  Arch Virol       Date:  1979       Impact factor: 2.574

6.  Comparative evaluation of human leukocyte and fibroblast interferon in the prevention of herpes simplex virus keratitis in a monkey model.

Authors:  D Neumann-Haefelin; R Sundmacher; R Skoda; K Cantell
Journal:  Infect Immun       Date:  1977-08       Impact factor: 3.441

7.  Human fibroblast interferon for clinical trials: production, partial purification, and characterization.

Authors:  A Billiau; J V Damme; F V Leuven; V G Edy; M De Ley; J J Cassiman; H Van de Berghe; P De Somer
Journal:  Antimicrob Agents Chemother       Date:  1979-07       Impact factor: 5.191
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.